HU195806B - Process for producing new piperazinyl-benzisothiazol- and piperazinyl-benzisoxasol-derivatives - Google Patents

Process for producing new piperazinyl-benzisothiazol- and piperazinyl-benzisoxasol-derivatives Download PDF

Info

Publication number
HU195806B
HU195806B HU86744A HU74486A HU195806B HU 195806 B HU195806 B HU 195806B HU 86744 A HU86744 A HU 86744A HU 74486 A HU74486 A HU 74486A HU 195806 B HU195806 B HU 195806B
Authority
HU
Hungary
Prior art keywords
piperazinyl
benzisothiazole
piperazin
formula
benzisothiazol
Prior art date
Application number
HU86744A
Other languages
Hungarian (hu)
Inventor
Davis L Jun Temple
Joseph P Yevich
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of HU195806B publication Critical patent/HU195806B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Description

A találmány tárgya eljárás piperazinil-benzizotiazol- vagy piperazinil-benzoizoxazol származékok és savaddíciós sóik előállítására.The present invention relates to a process for the preparation of piperazinyl benzisothiazole or piperazinyl benzoisoxazole derivatives and their acid addition salts.

A 190.997 lajstromszámú magyar szabadalmi leírás olyan (I) általános képletű vegyületeket ismertet, aholHungarian Patent Publication No. 190,997 discloses compounds of formula I wherein

R jelentése (a), (b), (c), (d), (e) vagy (f) általános képletű csoport, ahol n jelentése 3 vagy 4, Rj és R2 jelentése egymástól függetlenül rövidszénláncú, 1-4 szénatomot tartalmazó alkilcsoport,R is a radical of formula (a), (b), (c), (d), (e) or (f) wherein n is 3 or 4; R1 and R2 are each independently lower alkyl having from 1 to 4 carbon atoms. .

Y jelentése oxigénatom vagy kénatom, és jelentése hidrogénatom vagy halogénatom.Y is oxygen or sulfur, and is hydrogen or halogen.

A találmány szerinti vegyületek üj közbenső termékek az (I) általános képletű vegyületek előállításánál.The compounds of the invention are new intermediates for the preparation of compounds of formula (I).

A jelen találmány szerinti intermedierek (III) általános képletű vagy (IV) képletű vegyületek. A (III, általános képletbenThe intermediates of the present invention are compounds of Formula III or Formula IV. In the formula (III)

Y jelentése oxigénatom vagy kénatom.Y is oxygen or sulfur.

A találmány szerinti píperazinil-benzizotiazol- ós benzizoxazol-származékokat úgy állítjuk elő, hogy valamely (II) általános képletű 3-klór-l,2-benzizotiazolt vagy 3-klór-1,2-benzizoxazolt vagy (Ila) képletű 3-klór-2,1-benzizotiazolt emelt hőmérsékleten fölöslegben vett piperazinnal reagáltatunk. A kiindulási 3-klór-l,2-benzizotiazolt például úgy állítjuk elő, hogy l,2-benzizotiazol-3(2H)-ont 4 órán át 100-140 ’C hőmérsékleten, foszforpentakloriddal reagáltatunk. Hasonló módon, az l,2-benzizoxazol-3-ont H. Boshagen (Bér. 100, 3326 (1967)) módszere szerint, foszforoxikloriddal és trietilaminnal kezelve alakítjuk át 3-klór-l,2-benzizoxazollá.The piperazinyl benzisothiazole benzisoxazole derivatives of the invention are prepared by reacting a 3-chloro-1,2-benzisothiazole of formula II or 3-chloro-1,2-benzisoxazole or a 3-chloro compound of formula IIa. 2,1-Benzisothiazole is reacted with excess piperazine at elevated temperature. For example, the starting 3-chloro-1,2-benzisothiazole is prepared by reacting 1,2-benzisothiazol-3 (2H) -one with phosphorus pentachloride at 100-140 ° C for 4 hours. Similarly, 1,2-benzisoxazol-3-one is converted to 3-chloro-1,2-benzisoxazole by treatment with phosphorus oxychloride and triethylamine according to the method of H. Boshagen (Bér. 100, 3326 (1967)).

A találmány szerinti eljárást a továbbiakban - a találmány oltalmi körének szűkítése nélkül - példákkal szemléltetjük.The invention is further illustrated by the following non-limiting examples.

I. PéldaExample I

3-(Piperazin-I-iI)-l,2-benzizotiazo)3- (piperazin-l-yl) -l, 2-benzisothiazole)

37,8 g (0,235 mól) 3-klór-l,2-benzizotiazol ée 304,2 g (3,53 mól) piperazin elegyét argon atmoszférában, 20 órán át 120 ’C hőmérsékleten tartjuk egy zárt edényben. Utána az elegyel feloldjuk 2 1 vízben, és a vizes oldatot diklór-metánnal többször kirázzuk. A diklór-metános oldatokat egyesítjük, magnézium-szulfáton megszárítjuk, és az oldószert csökkentett nyomáson ledesztilláljuk. A maradékot feloldjuk dietil-éterben, az 0)datlan részeket kiszűrjük, majd az oldószert csökkentett nyomáson ledesztilláljuk. Ily módon viszkózus olaj formájában 24,4 g (hozam: 47 %) 3-(piperazin-l-il)-l,2-benzizotiazol szabad bázist kapunk.A mixture of 37.8 g (0.235 mol) of 3-chloro-1,2-benzisothiazole and 304.2 g (3.53 mol) of piperazine was kept under argon at 120 ° C for 20 hours in a closed vessel. The mixture was then dissolved in 2 L of water and the aqueous solution was extracted several times with dichloromethane. The dichloromethane solutions were combined, dried over magnesium sulfate and the solvent was distilled off under reduced pressure. The residue was dissolved in diethyl ether, the non-volatiles were filtered off and the solvent was distilled off under reduced pressure. This gave 24.4 g (47%) of 3- (piperazin-1-yl) -1,2-benzisothiazole free base as a viscous oil.

A szabad bázis egy mintáját úgy alakítjuk sósavas sóvá, hogy dietil-éterben etanolos sÓBav-oldattal kezeljük, majd a sót metanol és etanol elegyéből átkristályositjuk. Ily módon analitikailag tiszta 3-(piperazin-l-iD-1,2-benzizotiazol-hidrokloridot kapunk, op.: 280 “C (bomlik).A sample of the free base was converted to the hydrochloric acid salt by treatment with ethanolic salt salt in diethyl ether and recrystallized from a mixture of methanol and ethanol. This gave 3- (piperazine-1D-1,2-benzisothiazole hydrochloride), analytically pure, m.p. 280 DEG C. (dec.).

Analízis a C11H13N3S.HCI képlet alapján:Analysis calculated for C11H13N3S.HCI:

számított: C: 51,66; H: 5,52; N: 16,43 %; talált: C: 51,34; II: 5,46; N: 16,16 %.Calculated: C, 51.66; H, 5.52; N, 16.43. Found: C, 51.34; II: 5.46; N: 16.16%.

2. PéldaExample 2

3-(Piperazin-1-)1)-1,2-benzizöxs zol3- (Piperazine-1-) -1) -1,2-benzisoxazole

19,6 g (0,128 mól) 3-klór-l,2-benzjzoxazol és 110 g (1,28 mól) piperazin elegyet zárt edényben, 20 órán ót 120 ’C hőmérsékleten ta-tjuk. Utána az elegyet vizzel hígítjuk, és a vizes oldatot diklór-metánnal többször kirázzuk. A diklór-metános részeket egyesítjük, magnézium-szulfáton megszárítjuk, ée az oldószert csökkentett nyomáson ledesztilláljuk. Ily módon 21,2 g (hozam: 82 %) 3-(pipera.,in-l-íl)~] ,2-benzizoxazol szabad bázist kapunk.A mixture of 3-chloro-1,2-benzoxoxazole (19.6 g, 0.128 mol) and piperazine (110 g, 1.28 mol) was kept in a sealed vessel for 20 hours at 120 ° C. The mixture was diluted with water and the aqueous solution was extracted several times with dichloromethane. The dichloromethane fractions were combined, dried over magnesium sulfate and the solvent was distilled off under reduced pressure. This gave 21.2 g (82%) of 3- (piperazin, in-1-yl) -1,2-benzisoxazole free base.

A szabad bázis egy mintáját sósavas sóvá alakítjuk, és a sót metanol és etanol elegyéböl átkristályoBÍtjuk. Ily módon analítikailag tiszta 3-(piperazin-l-il)-l,2-benzizoxazol-hidrokloridot kapunk, op.: 326 “C (bomlik).A sample of the free base was converted to the hydrochloric acid salt and recrystallized from a mixture of methanol and ethanol. This gave analytically pure 3- (piperazin-1-yl) -1,2-benzisoxazole hydrochloride, m.p. 326 ° C (dec.).

Analízis a CnHnNsO.NCl képlet alapján:Analysis based on the formula CnHnNsO.NCl:

számított: C: 55,12; H: 5,89; N: 17,54 %; talált: C: 55,25; H: 5,82; N: 17,53 %.Calculated: C, 55.12; H, 5.89; N: 17.54%; Found: C, 55.25; H, 5.82; N: 17.53%.

3. PéldaExample 3

8- {4-(4-(1,2-ben zizotiazol-3-il)-plperazin-l~ill-bi}til)-8-azaepiro[4,5] dekán-7,9-dion (a találmány szerinti intermedierek felhasználása: referencia példa).8- {4- (4- (1,2-Benzisothiazol-3-yl) -piperazin-1-yl-bi} ethyl) -8-azaepiro [4,5] decane-7,9-dione (the invention) (use of intermediates according to Reference Example).

A) módszerMethod A)

24,3 g (0,11 mól) 3-<piperazin-l-il)-l,2-benzizotiazol, 33,5 g (0,11 mól) 8-(4-bróm-butil)-8-azaspiro-[4,5) dekán-7,9-dion,3- (piperazin-1-yl) -1,2-benzisothiazole (24.3 g, 0.11 mol), 8- (4-bromobutyl) -8-azaspiro- (33.5 g, 0.11 mol). [4,5] decane-7,9-dione,

32,4 g (0,23 mól) vízmentes kálium-karbonát és 3,9 g (0,023 mól) kálium-jodid 1 1 acetonitr llel készült elegyét 20 órán át keverés közben forraljuk. Utána az oldatlan részeket kiszűrjük, a szűrletröl az oldószert csökkentett nyomáson ledesztilláljuk és a maradékot feloldjuk 350 ml kloroformban. Az oldatlan részeket kiszűrjük, és a szűrletröl az oldószert csökkentett nyomáson ledesztilláljuk. A maradékot dietil-éterrel eldörzsöljük, behütjük és n kivált szilárd anyagot kiszűrjük. Ezt a szilárd terméket acetonitrilből, csontBzéniel derítve átkristályositjuk. Ily módon első generációként 25,1 g (op.: 120-124 ’C), második generációként 6,0 g (op.: 123-126 °C) cím szerinti vegyület szabad bázist kapunk, tehát az ŐBszhozam 31,1 g (64 %). B terméket acetonitrilből átkristályosítva analitikáikig tisztu 8-(4-( l,2-beozizotiazol-3-il)-2D piperazin-l-ill-butil)-8-aza-spiro[ 4,5 ] dekán-7,9-diont kapunk, op.: 124-126 ’C.A mixture of 32.4 g (0.23 mol) of anhydrous potassium carbonate and 3.9 g (0.023 mol) of potassium iodide in 1 L of acetonitrile is heated to reflux for 20 hours. The insolubles were filtered off, the filtrate was evaporated under reduced pressure and the residue was dissolved in 350 ml of chloroform. The insolubles were filtered off and the filtrate was evaporated under reduced pressure. The residue was triturated with diethyl ether, cooled and the solid separated by filtration. This solid product is recrystallized from acetonitrile, triturated with bone Benesene. In this way, the first generation of the free base of the title compound was 25.1 g (m.p. 120-124 ° C) and the second generation 6.0 g (m.p. 123-126 ° C) of 31.1 g (m.p. 64%). Product B is recrystallized from acetonitrile to afford analytical grade 8- (4- (1,2-beozisothiazol-3-yl) -2D-piperazin-1-yl-butyl) -8-aza-spiro [4,5] decane-7,9-dione. 124-126 ° C.

Analízis a CnHaaNíChS képlet alapján:Analysis by CnHaaNiChS:

számított: C: 65,42; H: 7,32; N: 12,72 talált: C: 65,45; H: 7,31; N: 12,75 %.Calculated: C, 65.42; H, 7.32; N, 12.72 Found: C, 65.45; H, 7.31; N: 12.75%.

NMR-spektrum (CDCIj): 1,60 (12Hm),· 2,57 (4H, s), 2,62 (611, m), 3,54 (4H, m), 3,79 (2H, m), 7,34 (2H, ra), 7,81 (2H, m).Nuclear Magnetic Resonance Spectrum (CDCl3): 1.60 (12Hm), 2.57 (4H, s), 2.62 (611, m), 3.54 (4H, m), 3.79 (2H, m) , 7.34 (2H, m), 7.81 (2H, m).

g szabad bázis forró izopropanollal kéezült azuazpenziójóhoz hozzáadunk 12,3 ml 5,7 normál etanoloe sósav-oldatot, az így kapott oldatot lehűtjük, a kivált csapadékot kiszűrjük és csökkentett nyomóson, 80 ’C hőmérsékleten megszárítjuk. Ily módon 29,6 g 8-(4-(4-( 1,2-benzizo tiazol-3-il)-piperazin-1-il)-butil}-8-aza-spiro[4,5]dekán-7,9-dién-hidrokloridot kapunk, op: 219-220 ’C.To a suspension of the free base in hot isopropanol (g) is added 12.3 ml of a 5.7N hydrochloric acid solution in ethanol (5.7 ml), the solution is cooled, the precipitate is filtered off and dried under reduced pressure at 80 ° C. 29.6 g of 8- (4- (4- (1,2-benzisothiazol-3-yl) piperazin-1-yl) butyl} -8-aza-spiro [4,5] decane-7) are thus obtained. 9-diene hydrochloride, m.p. 219-220 ° C.

Analízis a ChHjíNíOjS.HCI képlet alapján:Analysis based on the formula ChHjíNíOjS.HCI:

számítolt: C: 60,43; H: 6,98; N: 11,75 %; talált: C: 60,57; H: 6,98; N: 11,75 %.Calculated: C, 60.43; H, 6.98; N: 11.75%; Found: C, 60.57; H, 6.98; N: 11.75%.

NMR-spektrum (DMSO-de): 1,55 {12H, m),Nuclear Magnetic Resonance Spectrum (DMSO-d6): 1.55 (12H, m),

2,64 (4H, s), 3,40 (10H, m), 4,05 (2H, d, 12 OHz), 7,00 (2H,m), 8,10 (2H, m), 12,15 (IH, széles s).2.64 (4H, s), 3.40 (10H, m), 4.05 (2H, d, 12 Hz), 7.00 (2H, m), 8.10 (2H, m), 12, 15 (1H, bs).

A Bzabad bázis egy mintáját etanolos sósav-oldatot tartalmazó acetonitrilből kristályosítva 8-(4-[4-(l,2-benzizotiazol-3-il)-piperazin-l-Íl]-butil}-8-azas-piro[4,5]dekán-7,9-dion-dihidroklorid-dihidrátot kapunk: op.: 118-120 ’C.A sample of the Bzabad base was crystallized from acetonitrile containing ethanolic hydrochloric acid solution 8- (4- [4- (1,2-benzisothiazol-3-yl) piperazin-1-yl] butyl} -8-azaspiro [4 5] decane-7,9-dione dihydrochloride dihydrate, m.p. 118-120 ° C.

Analízis a C2«H3íN4O2S'2HC1.2H2O képlet alapján:Analysis based on the formula C2H3N4O2S'2HC1.2H2O:

számított: C: 52,45; H: 6,97; N: 10,20 %; talált: C: 52,68; H: 6,91; N: 10,29 %.Calculated: C, 52.45; H, 6.97; N: 10.20%; Found: C, 52.68; H, 6.91; N, 10.29%.

NMR-spektrum (DMSO-de): 1,55 (12H, m),Nuclear Magnetic Resonance Spectrum (DMSO-d6): 1.55 (12H, m),

2,64 (4H, s), 3,14 (4H, m), 3,58 (6H, m), 4,06 <2H, d, 12,OHz), 5,48 (4H, s), 7,50 (2H, m), 8,10 (2H, m), 11,60 (IH, széles s).2.64 (4H, s), 3.14 (4H, m), 3.58 (6H, m), 4.06 <2H, d, 12 Hz), 5.48 (4H, s), 7 , 50 (2H, m), 8.10 (2H, m), 11.60 (1H, broad s).

B) módezerModule B)

5,0 g (0,0228 mól) 3-(piperazin-l-il)-l,2-benzizotiazol, 9,8 g (0,0456 mól) 1,4-dibróm-butón és 7,9 g (0,057 mól) finoman elporitott, vízmentes kálium-karbonát 100 ml etanollal készült elegyét 16 órán át keverés közben forraljuk. Lehűtés utón az oldatlan részeket kiszűrjük, ée a szűrletröl az oldószert csökkentett nyomáson ledcsztilláljuk. A szilárd maradékot 70 ml izopropanollal felforraljuk, és az oldatlan részeket kiszűrjük. A szűrietet eredeti térfogatának körülbelül felére betÖményítjük, majd lehűtjük. Ily módon 5,58 g (hozam: 69,1 %) 8-l,2-henzizotiazol-3-il)-8-aza-5-azonÍa-Bpiro(4,5]dekón-bromidot kapunk, op.: 246,5-253 ’C.5.0 g (0.0228 mol) of 3- (piperazin-1-yl) -1,2-benzisothiazole, 9.8 g (0.0456 mol) of 1,4-dibromo-butone and 7.9 g (0.057) of mole) of finely pulverized, anhydrous potassium carbonate in 100 mL of ethanol is heated at reflux for 16 hours. After cooling, the insolubles were filtered off and the filtrate was distilled off under reduced pressure. The solid residue was boiled with isopropanol (70 mL) and the insolubles were filtered off. The filtrate was concentrated to about half its original volume and then cooled. Yield: 5.58 g (69.1%) of 8-1,2-benzisothiazol-3-yl) -8-aza-5-aza-Biro [4,5] decone bromide, m.p. 246 , 5-253'C.

Analízis a Ci5H2oBrN3S.l/4H20 képlet alapján: számított: C: 50,21; H: 5,76; N: 11,71;Analysis calculated for C 15 H 20 BrN 3 S · 1 / 4H 2 O: C, 50.21; H, 5.76; N: 11.71;

HxO: 1,26 %;H x O: 1.26%;

talált: C: 50,04; H: 5,68; N: 11,60;Found: C, 50.04; H, 5.68; N: 11.60;

H2O: 1,50 %.H2O: 1.50%.

2,52 g (0,0151 mól) 3,3-tetrametilén-glu-tárimid, 5,34 g (0,0151 mól) 8-(l,2-benzizoti-azol-3-il)-8-aza-5-azonia-spirol4,5]dekén-bromid és 2,4 g (0,0173 mól) porított kálium-karbonát 125 ml toluollal készült elegyét 24 órán ót keverve forraljuk, majd az oldatlan részeket kiszűrjük, és a ezürletről az oldószert ledesztillóljuk. A maradékot felvesszük forró toluolban, és forró heptánnal hígítjuk. A forró oldatot aktivszénnel kezeljük, a szenet kiszűrjük, majd lehűtjük/ Ily módon 4,46 g (hozam: 67,2 %) szilárd terméket kapunk, op.: 109,5-120 ’C.2.52 g (0.0151 mole) of 3,3-tetramethylene glutarimide, 5.34 g (0.0151 mole) of 8- (1,2-benzisothiazol-3-yl) -8-aza- A mixture of 5-azonia spirol4.5] decene bromide and 2.4 g (0.0173 moles) of powdered potassium carbonate in 125 ml of toluene was refluxed for 24 hours, the insolubles were filtered off and the solvent was distilled off from the filtrate. The residue was taken up in hot toluene and diluted with hot heptane. The hot solution is treated with activated carbon, the carbon is filtered off and cooled to give 4.46 g (67.2%) of a solid, m.p. 109.5-120 ° C.

E terméket metanolból átkristályositvaThis product was recrystallized from methanol

8-(4-[4-(4,5-benzjzotiazol-3-Íl)-piperazin-lil]-butil)-8-aza-spiro[4,5)-dekán-7,9-dion szabad bázist kapunk, op.: 127,5-130 ’C.8- (4- [4- (4,5-Benzothiazol-3-yl) piperazinyl) butyl) -8-aza-spiro [4,5] decane-7,9-dione is obtained as the free base. mp 127.5-130 ° C.

4. PéldaExample 4

5-(Piperazin-1-il)-2,1-benzizoiiazoi5- (piperazin-1-yl) -2,1-benzizoiiazoi

4,79 g (0,028 mól), Albert és munkatársai [J. Hét. Chem., 15, 529 (1978)] módszerével előállított 5-klór-2,l-benzizotiazol és 36,2 g (0,42 mól) piperazin elegyét zárt edényben 18 órán át 120 ’C hőmérsékleten tartjuk. Lehűtés után a reakcióelegyet feloldjuk 400 ml vízben, a vizes oldatot kirázzuk először dietil-éterrel, majd diklór-metánnal. Az egyesített szerves részeket magnézium-szulfáton megszárítjuk és az oldószert csökkentett nyomáson ledesztillóljuk. Ily módon szabad bázis formájában 5,67 g (hozam: 90 %) 5-(piperazin-l-il)-2,l-benzizotiazolt kapunk.4.79 g (0.028 mol), Albert et al., J. Med. Seven. Chem., 15, 529 (1978)] and a mixture of 5-chloro-2,1-benzisothiazole (36.2 g, 0.42 mol) and piperazine (18.2 g) were kept in a closed vessel at 120 ° C for 18 hours. After cooling, the reaction mixture was dissolved in water (400 mL), and the aqueous solution was partitioned between diethyl ether and dichloromethane. The combined organic layers were dried over magnesium sulfate and the solvent was distilled off under reduced pressure. This gave 5.67 g (90%) of 5- (piperazin-1-yl) -2,1-benzisothiazole as the free base.

A szabad bázis egy mintáját etanolos oldatban etanolos sósav-oldattal sósavas sóvá alakítjuk, ily módon analitikailag tiszta 5-(piperazin-I-il)-2,l-benzizotíazol-dihidrokloridol kapunk, op.: 274-276 ’C (bomlik).A sample of the free base was converted to the hydrochloride salt in ethanolic hydrochloric acid to give analytically pure 5- (piperazin-1-yl) -2,1-benzisothiazole dihydrochloridol, m.p. 274-276 ° C (decomposed).

Claims (3)

SZABADALMI IGÉNYPONTOKPATENT CLAIMS 1. Eljárás a (III) általános képletű és a (IV) képletű, ahol a képletbenA process for the preparation of a compound of formula (III) and (IV): wherein Y jelentése oxigénatom vagy kénaatom, piperazin-származékok és savaddíciós sóik előállítására, azzal jellemezve, hogy egy (II) általános képletű vagy egy (Ila) képletű vegyületet, ahol Ύ a fenti, piperazin felesleggel reagáltatunk emelt hőmérsékleten, majd kívánt esetben egy keletkezett szabad bázist savaddiciós sójává alakítunk.Y is an oxygen atom or a sulfur atom, for the preparation of piperazine derivatives and their acid addition salts, characterized in that a compound of the formula II or a compound of the formula IIa is reacted with an excess of piperazine at elevated temperature followed to an acid addition salt. 2. Az 1. igénypont szerinti eljárás 3-(piperazin-l-il)-l,2-benzizotiazol előállítására, azzal jellemezve, hogy 3-klór-l ,2-benzizoliazolból indulunk ki.Process for the preparation of 3- (piperazin-1-yl) -1,2-benzisothiazole according to claim 1, characterized in that it is started from 3-chloro-1,2-benzisothiazole. -3195806-3195806 3. Az 1. igénypont szerinti eljárás 3-(piperazin-l-il)-l,2-benzizoxazol elöállításá•a, azzal jellemezve, hogy 3-klór-l,2-benzizoazolból indulunk ki.3. A process according to claim 1 for the preparation of 3- (piperazin-1-yl) -1,2-benzisoxazole, starting from 3-chloro-1,2-benzisazole.
HU86744A 1981-12-23 1982-12-22 Process for producing new piperazinyl-benzisothiazol- and piperazinyl-benzisoxasol-derivatives HU195806B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/333,830 US4411901A (en) 1981-12-23 1981-12-23 Benzisothiazole and benzisoxazole piperazine derivatives

Publications (1)

Publication Number Publication Date
HU195806B true HU195806B (en) 1988-07-28

Family

ID=23304433

Family Applications (2)

Application Number Title Priority Date Filing Date
HU86744A HU195806B (en) 1981-12-23 1982-12-22 Process for producing new piperazinyl-benzisothiazol- and piperazinyl-benzisoxasol-derivatives
HU824132A HU190997B (en) 1981-12-23 1982-12-22 Process for preparing benzisothiazolyl-and benzisoxazolyl-piperazine derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU824132A HU190997B (en) 1981-12-23 1982-12-22 Process for preparing benzisothiazolyl-and benzisoxazolyl-piperazine derivatives

Country Status (26)

Country Link
US (1) US4411901A (en)
JP (2) JPS58110576A (en)
KR (1) KR870001022B1 (en)
AU (1) AU550780B2 (en)
BE (1) BE895469A (en)
CA (1) CA1205806A (en)
CH (2) CH659070A5 (en)
CY (1) CY1376A (en)
DE (1) DE3247530A1 (en)
DK (2) DK160939C (en)
ES (4) ES8401970A1 (en)
FI (1) FI78697C (en)
FR (2) FR2521561B1 (en)
GB (1) GB2114119B (en)
GR (1) GR77108B (en)
HK (1) HK5088A (en)
HU (2) HU195806B (en)
IE (1) IE54789B1 (en)
IT (1) IT1158037B (en)
KE (1) KE3718A (en)
LU (1) LU84550A1 (en)
NL (1) NL8204910A (en)
PT (1) PT76017B (en)
SE (2) SE453502B (en)
SG (1) SG30087G (en)
ZA (1) ZA828544B (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452799A (en) * 1981-12-23 1984-06-05 Mead Johnson & Company Benzisothiazole and benzisoxazole piperazine derivatives
US4524206A (en) * 1983-09-12 1985-06-18 Mead Johnson & Company 1-Heteroaryl-4-(2,5-pyrrolidinedion-1-yl)alkyl)piperazine derivatives
US4656280A (en) * 1984-03-07 1987-04-07 E. I. Du Pont De Nemours And Company Radioiodinated dopamine receptor ligand
US4590196A (en) * 1984-08-23 1986-05-20 Bristol-Myers Company Analgesic 1,2-benzisothiazol-3-ylpiperazine derivatives
JPH0625181B2 (en) * 1985-03-27 1994-04-06 住友製薬株式会社 New imide derivative
US4656173A (en) * 1985-04-24 1987-04-07 Bristol-Myers Company Antipsychotic benzisothiazole S-oxide compound
US4677104A (en) * 1985-05-06 1987-06-30 Bristol-Myers Company Antipsychotic fused-ring pyridinylpiperazine derivatives
JP2660407B2 (en) * 1986-09-26 1997-10-08 住友製薬株式会社 New imide derivatives
MX174210B (en) * 1987-02-17 1994-04-28 Pfizer PROCEDURE FOR THE PREPARATION OF ARILPIPERAZINYL-ALKYLENPHENYL-P-HETEROCICLICOS COMPOUNDS
CA1335289C (en) * 1987-10-26 1995-04-18 Fujio Antoku Piperidinyl benzisoxazole derivatives, their production and pharmaceutical use
AU2717288A (en) * 1987-11-12 1989-06-01 American Home Products Corporation Polycyclicamines with psychotropic activity
US4855430A (en) * 1987-11-12 1989-08-08 American Home Products Corporation Polycyclicamine with psychotropic activity
EP0316723B1 (en) * 1987-11-20 1992-09-30 Hoechst-Roussel Pharmaceuticals Incorporated 3-[4(1-Substituted-4-piperazinyl)butyl]-4-thiazolidinones a process for their preparation and their use as medicaments
US5801186A (en) 1987-11-20 1998-09-01 Hoechst Marion Roussel, Inc. 3- 4-(1-substituted-4-piperazinyl)butyl!-4-thiazolidinone and related compounds
US4880930A (en) * 1987-11-30 1989-11-14 New James S Psychotropic acyclic amide derivatives
US5116970A (en) * 1988-02-18 1992-05-26 New James S Psychotropic heterobicycloalkylpiperazine derivatives: 2. fused pyridazinones
US5001130A (en) * 1988-02-18 1991-03-19 Bristol-Myers Company Psychotropic heterobicycloalkylpiperazine derivatives
US5015740A (en) * 1988-08-05 1991-05-14 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
NZ230045A (en) * 1988-08-05 1990-11-27 Janssen Pharmaceutica Nv 3-piperazinylbenzazole derivatives and pharmaceutical compositions
US4957916A (en) * 1988-08-05 1990-09-18 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
WO1990002552A1 (en) * 1988-09-16 1990-03-22 Pfizer Inc. Antipsychotic 4-[4-(3-benzisothiazolyl)-1-piperazinyl]butyl bridged bicyclic imides
US4847252A (en) * 1988-10-25 1989-07-11 Bristol-Myers Company Method for alleviation of vascular headache
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US4956368A (en) * 1989-07-24 1990-09-11 Bristol-Myers Company Metabolites and prodrug formulations of 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione
US4968792A (en) * 1989-09-25 1990-11-06 American Home Products Corporation Psychotropic benzisothiazole derivatives
FR2671350A1 (en) * 1991-01-08 1992-07-10 Adir NOVEL BENZISOXAZOLE AND BENZISOTHIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME.
US5098904A (en) * 1990-06-27 1992-03-24 Bristol-Myers Squibb Company Cerebral function enhancing pyrimidinyl derivatives
JP2800953B2 (en) * 1990-07-06 1998-09-21 住友製薬株式会社 New imide derivatives
US5266571A (en) * 1992-01-09 1993-11-30 Amer Moh Samir Treatment of hemorrhoids with 5-HT2 antagonists
GB9226857D0 (en) * 1992-12-23 1993-02-17 Boyd Edward A Pharmaceutical compositions
CN1050604C (en) * 1993-02-04 2000-03-22 明治制果株式会社 Compound with antipsychotic effect
HUT69376A (en) * 1993-05-04 1995-09-28 Egyt Gyogyszervegyeszeti Gyar Process for preparing heterocyclic compounds
TR199700873T1 (en) 1995-02-28 1998-01-21 H. Lund-Beck A/S 4-Aminotetrahydrobenzisoxazole or -isothiazole compounds.
ATE199147T1 (en) * 1995-06-06 2001-02-15 Aventis Pharma Inc BENZISOXAZOLE AND INDAZOLE DERIVATIVES AS ANTIPSYCHOTICS
EP1757292A1 (en) 1997-09-05 2007-02-28 Pfizer Products Inc. Method of treating ocd and tic disorders
JP2002541098A (en) * 1999-04-06 2002-12-03 セプラコア インコーポレーテッド Methods and compositions for treating neuroleptic disorders and related disorders using ziprasidone metabolites
US7030142B1 (en) 1999-04-06 2006-04-18 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using ziprasidone metabolites
AU2003267801A1 (en) * 2002-10-28 2004-05-13 Warner-Lambert Company Llc Oxindole substituted piperazine derivatives
BR0316108A (en) * 2002-11-08 2005-09-27 Warner Lambert Co Phenylalkyl and pyridylalkyl piperazine derivatives and pharmaceutical composition comprising them
CA2670116C (en) 2006-11-22 2015-03-10 Seaside Therapeutics, Llc Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism
WO2013014665A1 (en) 2011-07-28 2013-01-31 Mapi Pharma Ltd. Intermediate compounds and process for the preparation of lurasidone and salts thereof
CN105669665A (en) * 2016-03-15 2016-06-15 烟台贝森医药科技有限公司 Preparation method of perospirone

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1595920B2 (en) * 1964-11-04 1978-08-10 Merck Patent Gmbh, 6100 Darmstadt 4- (co-piperazinoalkyl) pyrazoles, their salts and processes for their preparation
US3398151A (en) * 1966-02-01 1968-08-20 Mead Johnson & Co Azaspirodecanediones and azaspiroundecanediones
DE1695410A1 (en) * 1967-04-20 1971-04-08 Merck Patent Gmbh Process for the preparation of 1- (thiazolyl-5-alkyl) -4- (pyridyl-2) -piperazines
DE1670907B2 (en) * 1967-08-16 1976-07-22 Bayer Ag, 5090 Leverkusen N-DISUBSTITUTED 3-AMINO-1,2BENZISOTHIAZOLES AND THE METHOD OF MANUFACTURING THEIR
US3528989A (en) * 1967-11-14 1970-09-15 Colgate Palmolive Co 3-aminoalkyl derivatives of 2,1-benzisothiazoline
BE759371A (en) * 1969-11-24 1971-05-24 Bristol Myers Co HETEROCYCLICAL AZASPIRODECANEDIONES AND METHODS FOR THEIR PREPARATION
AR207986A1 (en) * 1974-07-01 1976-11-22 Sumitomo Chemical Co A PROCEDURE FOR PRODUCING 3- (N-SUBSTITUTED AMINOALKYL) -BENZ-2,1-ISOXAZOLE COMPOUNDS
US3940398A (en) * 1975-01-23 1976-02-24 E. R. Squibb & Sons, Inc. 2-[[4-(Azine or diazine or triazine)-1-piperazinyl]alkyl]-1H-benz[de]isoquinoline-1,3(2H)-diones
DE2734866A1 (en) * 1977-08-03 1979-02-22 Basf Ag NEW 1,2-BENZISOTHIAZOLES AND THE METHOD FOR PRODUCING THEM
US4182763A (en) * 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
DK251079A (en) * 1978-06-20 1979-12-21 Synthelabo METHOD OF PREPARATION OF PHENYLPIPERAZINE DERIVATIVES

Also Published As

Publication number Publication date
JPS58110576A (en) 1983-07-01
ES8503683A1 (en) 1985-04-01
GB2114119B (en) 1985-11-27
LU84550A1 (en) 1983-09-08
FR2521561B1 (en) 1986-10-10
FR2531431B1 (en) 1986-10-10
CA1205806A (en) 1986-06-10
KR840002832A (en) 1984-07-21
ES524946A0 (en) 1985-04-01
DE3247530A1 (en) 1983-06-30
KE3718A (en) 1987-04-16
GB2114119A (en) 1983-08-17
SE453502B (en) 1988-02-08
JPH0517457A (en) 1993-01-26
US4411901A (en) 1983-10-25
DK307590D0 (en) 1990-12-28
SE8702389L (en) 1987-06-09
CH656617A5 (en) 1986-07-15
DK160939C (en) 1991-10-21
CY1376A (en) 1987-08-07
CH659070A5 (en) 1986-12-31
PT76017B (en) 1985-12-20
FI78697C (en) 1989-09-11
JPH0577669B2 (en) 1993-10-27
SE8207350D0 (en) 1982-12-22
SG30087G (en) 1987-07-17
HU190997B (en) 1986-12-28
ES518168A0 (en) 1984-01-16
FI78697B (en) 1989-05-31
DK160939B (en) 1991-05-06
DK162601B (en) 1991-11-18
IE823053L (en) 1983-06-23
FR2531431A1 (en) 1984-02-10
FR2521561A1 (en) 1983-08-19
BE895469A (en) 1983-06-23
DK307590A (en) 1990-12-28
SE8207350L (en) 1983-08-10
IT8249709A0 (en) 1982-12-21
HK5088A (en) 1988-01-29
IT1158037B (en) 1987-02-18
IE54789B1 (en) 1990-02-14
KR870001022B1 (en) 1987-05-23
ES525471A0 (en) 1985-02-01
SE462162B (en) 1990-05-14
ES8503349A1 (en) 1985-02-01
AU9087282A (en) 1983-06-23
ES525470A0 (en) 1985-02-01
PT76017A (en) 1983-01-01
AU550780B2 (en) 1986-04-10
SE8702389D0 (en) 1987-06-09
DK162601C (en) 1992-05-11
DK566282A (en) 1983-06-24
NL8204910A (en) 1983-07-18
ZA828544B (en) 1983-09-28
ES8401970A1 (en) 1984-01-16
ES8502991A1 (en) 1985-02-01
FI824379A0 (en) 1982-12-20
GR77108B (en) 1984-09-06
FI824379L (en) 1983-06-24

Similar Documents

Publication Publication Date Title
HU195806B (en) Process for producing new piperazinyl-benzisothiazol- and piperazinyl-benzisoxasol-derivatives
KR970009728B1 (en) Process for the preparation of -2-(2-(4-((4chlorophenyl)phenylmethyl-1-piperazinyl)ethoxy)-acetic acid and tis dihydrochloride
DK153399B (en) METHOD OF ANALOGUE FOR THE PREPARATION OF 2,4-DIAMINOQUINAZOLINE COMPOUNDS OR PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALTS AND 4-AMINOQUINAZOLINE COMPOUNDS FOR USE AS THE EXAMPLE
HU180045B (en) Process for producing new amino-thiasole derivatives
CA1237722A (en) 2-¬4-¬(4,4,-dialkyl-2,6,-piperidinedion-1- yl)butyl|-1-piperazinyl| pyridines
US7288658B2 (en) Process for preparation of pyridine derivatives
US4010267A (en) Benzodioxole compounds
CS198297B2 (en) Method of producing derivatives of urea
US3509153A (en) 5-phenyl (or 5-phenylalkyl)-2-(omega-(4-phenyl-1-piperazinyl)alkyl)tetrazoles
DK156722B (en) ANALOGY PROCEDURE FOR PREPARING 2-PIPERAZINOPYRIMIDINE DERIVATIVES
SE408710B (en) ANALOGICAL PROCEDURE FOR THE PREPARATION OF OCTAHYDROPYRAZINO (2 &#39;, 1&#39;: 6,1) PYRIDO (3,4) INDOLES
US4112092A (en) 1-Naphthylmethyl-4-(thiazolyl-2)-piperazines
HU220971B1 (en) Process for producing 0-(3-amino-2-hidroxy-propyl)-hidroxim acid halogenids
SU526291A3 (en) The method of obtaining derivatives of theophylline
PL95852B1 (en) METHOD OF MAKING NEW ACYLATED DERIVATIVES OF 2-AMINOTHIAZOLES
US5260297A (en) 2-imino-3-alkylbenzothiazoline derivatives bearing a heterocyclic substituent on the alkyl group, their preparation and medicinal products containing them.
JPH0386871A (en) Substituted 2-imino-3- alkylbenzothiazolines
SU999967A3 (en) Process for producing 6-n-substituted 6-amino-3-pyridazinyl hydrizines or their salts
FI61312C (en) FRAME FOR THE PREPARATION OF THERAPEUTIC THERAPEUTIC 10PIPERAZINYL DIBENSO (B, F) TIEPINDERIVAT
RU2298553C1 (en) Method for preparing 2-(3&#39;,5&#39;-diamino-1&#39;,2&#39;,4&#39;-triazol-1&#39;-yl)-4-r1-5-r2-1,3-thiazoles
Manaev et al. Synthesis and reactions of dehydracetic acid difluoroborane complex
KR840001095B1 (en) Process for preparation of novel chloro- and alkoxy -substituted-2,4-diaminoguinazolines
GB1570912A (en) Aromatic sulphonamido derivatives and process for their manufacture
HU193379B (en) Process for producing n-(/4-hydroxy-4-phenyl-1-pyridinyl/-alkilen)-aza-spiroalkanediones
US2794803A (en) Substituted pyridines and their preparation

Legal Events

Date Code Title Description
HU90 Patent valid on 900628
HMM4 Cancellation of final prot. due to non-payment of fee